Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery and Hisun Pharmaceuticals Partner on Bioproduction Cell Line

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Precisely engineered CHO cell line will enable faster, more efficient development in production of therapeutic antibodies.

Horizon Discovery announced it has entered into an agreement with Hisun Pharmaceuticals (Hisun) to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be using Horizon’s glutamine synthetase (GS) double knock-out cell line for use in therapeutic antibody manufacturing. Financial terms of the agreement were not disclosed.

Horizon has engineered the CHO cell line using its GENESIS™ gene editing technology, providing the most precisely engineered GS double knock-out available. The precision afforded by GENESIS results in an optimal final genotype, with complete control over the desired genomic alterations and with no unwanted off-target effects.

GS is a critical enzyme in the metabolism of the amino acid L-glutamine which is often used as a selection marker in the production of recombinant proteins. GS-negative CHO cell lines have proven to be a valuable resource for stringent selection of high producing lines and accelerating the development of cell lines within the Bioproduction industry, offering significant advantages over traditional methods that use an expensive and toxic chemical inhibitor of GS.

Haibin Wang, Senior Vice President, Hisun Pharmaceuticals, said: “Hisun’s competitive edge comes from our focus on pioneering technology and quality product. Horizon’s gene engineering technology is unique in the level of precision it can deliver, and therefore offers great advantages in quality and efficiency for industrial cell line engineering. Partnering with forward-looking leaders in their field, such as Horizon, is a key part of our strategy to provide innovative and quality products to our patients.”

“We are delighted to be working with Hisun on the final development stage for this cell line, the first of several Horizon projects aimed at GMP production of therapeutic proteins,” commented Dr Brian Burke, Business Development Manager at Horizon. “Cell line development has yet to match the gains made in media and feed technology development.  Precision gene editing will be a key driver for cell line development, and by selective partnering with leaders like Hisun, Horizon intends to accelerate this process.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!